Literature DB >> 27896096

Peripheral leukocyte anomaly detected with routine automated hematology analyzer sensitive to adipose triglyceride lipase deficiency manifesting neutral lipid storage disease with myopathy/triglyceride deposit cardiomyovasculopathy.

Akira Suzuki1, Hironori Nagasaka2, Yasuhiro Ochi3, Kazuhiro Kobayashi4, Hiroshi Nakamura5, Daisaku Nakatani1, Satoshi Yamaguchi1, Shinobu Yamaki6, Atsushi Wada3, Yoshihisa Shirata7, Shu-Ping Hui6, Tatsushi Toda4, Hiroshi Kuroda8, Hitoshi Chiba6, Ken-Ichi Hirano1.   

Abstract

Adipose triglyceride lipase (ATGL) deficiency manifesting neutral lipid storage disease with myopathy/triglyceride deposit cardiomyovasculopathy presents distinct fat-containing vacuoles known as Jordans' anomaly in peripheral leucocytes. To develop an automatic notification system for Jordans' anomaly in ATGL-deficient patients, we analyzed circulatory leukocyte scattergrams on automated hematology analyzer XE-5000. The BASO-WX and BASO-WY values were found to be significantly higher in patients than those in non-affected subjects. The two parameters measured by automated hematology analyzer may be expected to provide an important diagnostic clue for homozygous ATGL deficiency.

Entities:  

Keywords:  ATGL, adipose triglyceride lipase; Adipose triglyceride lipase deficiency; Automated hematology analyzer; BASO-WX and BASO-WY; Circulatory neutrophils; Jordans' anomaly; NLSD-M, Neutral lipid storage disease with myopathy (NLSD-M); TGCV, triglyceride deposit cardiomyovasculopathy; Triglyceride deposit cardiomyovasculopathy

Year:  2014        PMID: 27896096      PMCID: PMC5121313          DOI: 10.1016/j.ymgmr.2014.05.001

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


Introduction

Adipose triglyceride lipase (ATGL, EC 3.1.1.3) deficiency is caused by mutations in ATGL gene, also called PNPLA2 [1], [2], [3]. It presents profound lipid accumulation mainly in skeletal and cardiac muscles, manifesting neutral lipid storage disease with myopathy (NLSD-M)/triglyceride deposit cardiomyovasculopathy (TGCV) [3], [4], [5], [6], [7]. Only up to 40 patients have been reported globally [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13]. Most of the reported cases were diagnosed in adulthood except for one case each in childhood and adolescence [12], [13]. In adulthood, the myopathy and cardiomyopathy can be severe and rapidly progressive, and refractory to various therapies. Affected patients with ATGL deficiency exclusively exhibit persistent lipid droplets in the cytoplasm of circulatory neutrophils known as Jordans' anomaly (Fig. 1A) [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13]. In earlier life, clinical symptoms seem to be absent or minimal in most cases, however Jordans' anomaly has been documented in subclinical or preclinical adolescents with ATGL deficiency [12], [13]. Blood smear examination with May-Giemsa staining has been used for the detection of vacuoles in leucocytes. This report concerns a simple, easy and feasible laboratory test using a routine automated hematological analyzer that detects leukocyte abnormalities in patients with myopathy or cardiomyovasculopathy and possibly leads to a diagnosis of homozygous ATGL deficiency.
Fig. 1

(A) A representative image of May-Giemsa staining of blood smears from ATGL-deficient patients. Lipid droplets in peripheral leucocytes known as Jordans' anomaly were found in the neutrophils from all the ATGL-deficient patients. (B) Typical BASO scattergrams of control's blood (left) or homozygote's blood (right). Horizontal (X) and vertical (Y) axes indicate side and forward scattered light intensity, respectively. Colors indicate basophils (white dots), degenerated white blood cells (pale blue dots), and the other small particles (blue dots, white arrow). In these samples, BASO-WX and BASO-WY values are 79.5 and 60.3 (left, healthy), or 362.9 and 139.5 (right, patients), respectively. (C) Scatter plot of BASO-WX and BASO-WY. BASO-WX/BASO-WY values for ATGL-deficient patients (●), heterozygous ATGL carriers (○), controls (X). BASO-WX/BASO-WY values for ATGL-deficient patients were significantly higher than in other groups in Welch's t-test.

Methods

Subjects and specimens

Four homozygous ATGL-deficient patients (3 males and 1 female, 45–60 years of age) (Table 1) and nine heterozygous family members (4 males and 5 females, 17–83 years), lacking ATGL deficiency-associated symptoms, were enrolled. The diagnosis of ATGL deficiency was based on gene analyses together with clinical manifestations of myopathy, including easy fatigability, reduced exercise capability and limb weakness, and cardiomyopathy. Forty-three healthy subjects (14 males and 29 females, 32–84 years) lacking the mutations in ATGL gene and having no abnormality under the physical examination were also enrolled as controls. The peripheral blood specimens were collected with EDTA. Written informed consent was obtained from the enrolled subjects before study initiation.
Table 1

Backgrounds of four adipose triglyceride lipase-deficient patients.

CaseSexGene mutationsReferencePresent ageCardiac functionSkeletal myopathyAge at diagnosisa(Jordan's anomaly)
1Mc.865C>T650NYHA4Mild41
2Mc.696+1G>C847NYHA4Mild33
3F477_478dupCTCC445NYHA1Severe31
4Mc.576delC1160NYHA3Mild58

All patients showed Jordans' anomaly in their blood smears at the diagnoses.

Sample analysis

Blood specimens were analyzed by the XE-5000 automated hematology analyzer (Sysmex, Kobe, Japan) and investigated all the parameters including WBC/BASO channel of the XE-5000 to screen for Jordans' anomaly. In the WBC/BASO channel, its hemolyzing reagent, Stromatolyzer FB (Sysmex), lyses plasma membranes of cells other than basophils in the specimen and, as a result, the cytosolic components of non-basophils are released from the cells. Lipid droplets released from ATGL-deficient leukocytes which retain their shape in aqueous environment due to their own lipid monolayer membranes can be detected as smaller particles [14]. Thus, in the WBC/BASO scattergram, almost intact basophils, nucleus of non-basophil leukocytes, and relatively large cytosolic components including lipid droplets or debris are detected as particles (Fig. 1B). Parameters named BASO-WX and BASO-WY, which stand for the spread of particle distribution in side and forward scattered light, respectively, are calculated in the WBC/BASO channel.

Statistical analysis

An analysis of Welch's t-test was performed to compare differences in BASO-WX and BASO-WY values between homozygous and heterozygous or controls. p < 0.05 was set to be statistically significant.

Results and discussion

After confirming that all the specimens from the four ATGL-deficient patients had Jordans' anomaly by examining their blood smears stained with May-Giemsa (Fig. 1A), we investigated all the parameters of the XE-5000 automated hematology analyzer to find any change corresponding to Jordans' anomaly. The WBC/BASO scattergram revealed an increased number of small particles in the homozygous patients, typically shown as the blue dots in Fig. 1B (white arrow in the right panel). Such change was not observed in the controls (Fig. 1B left) and in the heterozygote carriers (data not shown). The observed small particles are supposed to be the lipid droplets released from the patients' leukocytes, because lipid droplets can be expected to retain their spherical forms with neutral lipid core and phospholipid monolayer surface in this aqueous environment [14]. The BASO-WX and BASO-WY values obtained from the WBC/BASO channel of XE-5000 were significantly higher in the ATGL-deficient patients than those in the non-affected heterozygotes and the controls (Fig. 1C): 251.8 ± 100/132.0 ± 7.7 (BASO-WX/BASO-WY, mean ± SD) for the ATGL-deficient patients, 80.2 ± 3.8/74.8 ± 8.2 for the heterozygous carriers, and 80.4 ± 5.5/70.3 ± 8.2 for the controls. We, therefore, anticipate that detection of the leucocyte abnormality in a routine automated hematological analysis may be a first step toward the diagnosis of homozygous ATGL deficiency. We further suggest that detected positive subjects should undergo more detailed analyses, including ATGL gene analyses, to establish the diagnosis in the clinical practice. In homozygous ATGL deficiency, once the clinical presentations of myopathy and cardiomyopathy occur, it has been difficult so far to regress or resolve symptoms through any conventional treatments [3], [4], [5], [6], [7], [8], [9], [10], [11], [12]. We reported two patients with severe cardiomyovasculopathy and heart failure requiring cardiac transplantation [6], [8]. We recently provided data indicating that up-regulation of peroxisome proliferated activated receptor-γ and the related genes may promote triglyceride accumulation in the skeletal and cardiac muscles in ATGL deficiency [8]. We believe that the development of an easy method to detect cellular triglyceride accumulation is desired. It is quite likely that the change in the leukocyte emerges before the development of myopathy or cardiomyovasculopathy, as it does in other congenital lipid storage diseases such as Gaucher's and Niemann–Pick disease, which show distinct lipid storage in circulatory and bone marrow macrophages [15]. In our settings, heterozygous carriers could not be differentiated from control subjects, even though Jordans' anomaly has been reported in some heterozygous ATGL deficiency [16]. We speculate that one of the reasons for this may be that heterozygous leukocytes may have enough ATGL enzymatic activity to reduce the number and/or size of intracellular lipid droplets, so that BASO-WX and BASO-WY parameters were not different between heterozygous and control subjects. It has been known that Jordans' anomaly in leukocytes is present not only in ATGL deficiency but also in Chanarin–Dorfman syndrome also called NLSD with ichthyosis, which is caused by deficiency of the protein CGI-58, an activator of the ATGL enzyme [17], [18]. Further, in carnitine palmitoyltransferase deficiency type 1, a fatty acid beta-oxidation disorder engendering hypoglycemia and acidosis, this anomaly can sometimes be found in blood smears [19]. It would be of interest to know whether the present system can detect leucocyte abnormalities in these disorders, even we did not have the chance to test the possibility because of the disease rarity. The sensitivity and specificity of BASO-WX and BASO-WY for ATGL deficiency remains to be investigated, however we believe that this automatic detection of changes in leukocytes with an automated hematology analyzer may provide an earlier diagnostic clue for ATGL deficiency to clinicians, who encounter patients with neuromuscular and cardiovascular disorders, whose causes are unknown. In order to increase information on the natural history and pathophysiology in NLSD/TGCV patients, we have started an international registry system on the web (http://www.tgcv.org/r/home.html).

Conclusions

The BASO-WX and BASO-WY values obtained from automated hematology analyzer XE-5000 could help to detect Jordans' anomaly. A notification system using an automated hematology analyzer may prompt the earlier and easier diagnosis of homozygous ATGL deficiency.
  19 in total

1.  Triglyceride deposit cardiomyovasculopathy.

Authors:  Ken-ichi Hirano; Yoshihiko Ikeda; Nobuhiro Zaima; Yasuhiko Sakata; Goro Matsumiya
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

2.  Genetic mutations in adipose triglyceride lipase and myocardial up-regulation of peroxisome proliferated activated receptor-γ in patients with triglyceride deposit cardiomyovasculopathy.

Authors:  Ken-ichi Hirano; Tatsuya Tanaka; Yoshihiko Ikeda; Satoshi Yamaguchi; Nobuhiro Zaima; Kazuhiro Kobayashi; Akira Suzuki; Yasuhiko Sakata; Yasushi Sakata; Kunihisa Kobayashi; Tatsushi Toda; Norihide Fukushima; Hatsue Ishibashi-Ueda; Daniela Tavian; Hironori Nagasaka; Shu-Ping Hui; Hitoshi Chiba; Yoshiki Sawa; Masatsugu Hori
Journal:  Biochem Biophys Res Commun       Date:  2013-12-08       Impact factor: 3.575

3.  Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome.

Authors:  C Lefèvre; F Jobard; F Caux; B Bouadjar; A Karaduman; R Heilig; H Lakhdar; A Wollenberg; J L Verret; J Weissenbach; M Ozgüc; M Lathrop; J F Prud'homme; J Fischer
Journal:  Am J Hum Genet       Date:  2001-10-02       Impact factor: 11.025

Review 4.  Carnitine palmitoyltransferase deficiencies.

Authors:  J P Bonnefont; F Demaugre; C Prip-Buus; J M Saudubray; M Brivet; N Abadi; L Thuillier
Journal:  Mol Genet Metab       Date:  1999-12       Impact factor: 4.797

Review 5.  Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges.

Authors:  Pascal Laforêt; Christine Vianey-Saban
Journal:  Neuromuscul Disord       Date:  2010-08-05       Impact factor: 4.296

6.  The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition.

Authors:  Kumi Tauchi-Sato; Shintaro Ozeki; Toshiaki Houjou; Ryo Taguchi; Toyoshi Fujimoto
Journal:  J Biol Chem       Date:  2002-09-06       Impact factor: 5.157

7.  Clinical and genetic characterization of Chanarin-Dorfman syndrome.

Authors:  Claudio Bruno; Enrico Bertini; Maja Di Rocco; Denise Cassandrini; Giuseppe Ruffa; Teresa De Toni; Marco Seri; Marco Spada; Giovanni Li Volti; Adele D'Amico; Federica Trucco; Marcello Arca; Carlo Casali; Corrado Angelini; Salvatore Dimauro; Carlo Minetti
Journal:  Biochem Biophys Res Commun       Date:  2008-03-11       Impact factor: 3.575

Review 8.  A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy: a case report and literature review.

Authors:  Kimihiko Kaneko; Hiroshi Kuroda; Rumiko Izumi; Maki Tateyama; Masaaki Kato; Koichiro Sugimura; Yasuhiko Sakata; Yoshihiko Ikeda; Ken-Ichi Hirano; Masashi Aoki
Journal:  Neuromuscul Disord       Date:  2014-04-21       Impact factor: 4.296

9.  A novel clinical entity: triglyceride deposit cardiomyovasculopathy.

Authors:  Ken-Ichi Hirano
Journal:  J Atheroscler Thromb       Date:  2009-09-03       Impact factor: 4.928

10.  Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals.

Authors:  Raymond Y Wang; Olaf A Bodamer; Michael S Watson; William R Wilcox
Journal:  Genet Med       Date:  2011-05       Impact factor: 8.822

View more
  4 in total

Review 1.  Neutral Lipid Storage Disease Associated with the PNPLA2 Gene: Case Report and Literature Review.

Authors:  Makoto Samukawa; Naoko Nakamura; Makito Hirano; Miyuki Morikawa; Hanami Sakata; Ichizo Nishino; Rumiko Izumi; Naoki Suzuki; Hiroshi Kuroda; Kensuke Shiga; Kazumasa Saigoh; Masashi Aoki; Susumu Kusunoki
Journal:  Eur Neurol       Date:  2020-06-19       Impact factor: 1.710

2.  Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder.

Authors:  Ming Li; Ken-Ichi Hirano; Yoshihiko Ikeda; Masahiro Higashi; Chikako Hashimoto; Bo Zhang; Junji Kozawa; Koichiro Sugimura; Hideyuki Miyauchi; Akira Suzuki; Yasuhiro Hara; Atsuko Takagi; Yasuyuki Ikeda; Kazuhiro Kobayashi; Yoshiaki Futsukaichi; Nobuhiro Zaima; Satoshi Yamaguchi; Rojeet Shrestha; Hiroshi Nakamura; Katsuhiro Kawaguchi; Eiryu Sai; Shu-Ping Hui; Yusuke Nakano; Akinori Sawamura; Tohru Inaba; Yasuhiko Sakata; Yoko Yasui; Yasuyuki Nagasawa; Shintaro Kinugawa; Kazunori Shimada; Sohsuke Yamada; Hiroyuki Hao; Daisaku Nakatani; Tomomi Ide; Tetsuya Amano; Hiroaki Naito; Hironori Nagasaka; Kunihisa Kobayashi
Journal:  Orphanet J Rare Dis       Date:  2019-06-11       Impact factor: 4.123

Review 3.  Neutral Lipid Storage Diseases as Cellular Model to Study Lipid Droplet Function.

Authors:  Sara Missaglia; Rosalind A Coleman; Alvaro Mordente; Daniela Tavian
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

4.  Left-dominant arrhythmogenic cardiomyopathy with a nonsense mutation in DSP.

Authors:  Yuichiro Tsuruta; Daisuke Sueta; Seiji Takashio; Seitaro Oda; Kenij Sakamoto; Koichi Kaikita; Koichi Kato; Seiko Ohno; Minoru Horie; Kenichi Tsujita
Journal:  ESC Heart Fail       Date:  2020-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.